Saturday 17 October 2026
Export YI’s income statement to Excel — free account
111, Inc. Sponsored ADR
YI Healthcare Medical Distribution
111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024. In the quarter to March 2026, revenue fell 29.6%, EPS fell 200.0%, free cash flow fell 185.7% and total debt rose 82.5%, each against the same quarter a year earlier.
3.09
0.00
0.00%
Follow YI
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.03 | 0.02 | 0.01 | 0.03 | |
P/FCF ratio |
0.00 | 0.00 | 2.75 | 0.00 | |
P/Operating CF |
(7.40) | 7.35 | 4.95 | (4.31) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.01 | (0.01) | (0.02) | 0.02 | |
EV/EBITDA |
0.00 | 11.29 | 112.75 | 0.00 | |
EV/Operating CF |
0.91 | (3.55) | (2.25) | (3.16) | |
EV/FCF |
(5.29) | 1.06 | (4.73) | (1.80) | |
Quick Ratio |
0.37 | 0.38 | 0.45 | 0.34 | |
Current Ratio |
1.13 | 1.07 | 1.09 | 1.08 | |
Net Debt/EBITDA |
(3,684.23) | 169.59 | 1,147.50 | 6.96 | |
Debt/Assets |
6.86% | 6.85% | 8.53% | 13.32% | |
Debt/Equity |
(0.25) | (0.24) | (0.26) | (0.34) | |
Asset Turnover |
5.34 | 4.75 | 5.16 | 5.16 | |
Operating CF/Net income |
3.07 | (2.96) | (1.79) | 2.48 | |
Capex/Depreciation |
— | — | (0.37) | — | |
Interest Coverage |
0.01 | (0.32) | (0.03) | (2.54) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
2.61% | 2.58% | 2.84% | 2.99% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(1.81) | (2.83) | (5.12) | (2.10) | |
Graham Number |
14.50 | 14.65 | 16.33 | 19.85 | |
Earnings Yield |
(11.76%) | (18.46%) | (39.06%) | (21.47%) | |
Free Cash Flow Yield |
(4.29%) | (35.09%) | 36.37% | (36.12%) | |
Revenue per Share |
51.56 | 48.39 | 50.58 | 38.93 | |
Operating CF per Share |
(0.96) | 0.62 | 0.52 | (1.51) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.96) | 0.62 | 0.52 | (1.51) | |
Cash per Share |
8.25 | 8.99 | 10.05 | 6.54 | |
Shareholders Equity per Share |
(11.12) | (11.36) | (11.86) | (12.51) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(11.12) | (11.36) | (11.86) | (12.51) | |
Free Cash Flow |
(8.37) | 5.39 | 4.50 | (13.30) | |
Working Capital |
36.89 | 22.72 | 24.48 | 20.81 | |
Capital Expenditures |
— | — | (0.62) | — | |
Net Current Asset Value |
(111.88) | (112.14) | (113.95) | (120.59) | |
EV/EBIT |
0.00 | 11.29 | 112.72 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
46.82 | 50.07 | 46.87 | 32.07 | |
Average Payables |
218.42 | 245.12 | 209.61 | 203.65 | |
Average Inventory |
183.28 | 197.24 | 166.43 | 166.20 | |
Average Assets |
364.76 | 390.21 | 348.28 | 319.93 | |
Average Common Equity |
(91.12) | (94.80) | (96.67) | (101.44) |
Columns are period end dates